Brilliant Violet 605™ anti-mouse CD183 (CXCR3)

Antibodies Single
Sony
S18001A
Flow Cytometry
Rat IgG2b, κ
Mouse
Mouse CXCR3-transfectants
50 µg
1379575
$313.00

Description

CD183, also known as CXCR3, is a member of the C-X-C chemokine family, characterized by a pair of cysteine residues separated by a single amino acid. CXCR3 is a 38 kD seven pass transmembrane receptor coupled to G-protein. It mediates Ca2+ mobilization and chemotaxis in response to C-X-C chemokines, such as IP10 (CXCL10), MIG (CXCL9), I-TAC (CXCL11) and PF4 (CXCL4). CXCR3 is expressed primarily on activiated T lymphocytes, NK cells, and some epithelial cells and endothelial cells. It is not expressed on B cells, monocytes, or granulocytes.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.



This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.